The purpose of this study is to compare relapse-free survival between participants with
FLT3/ITD AML in first morphologic complete remission (CR1) who undergo hematopoietic stem
cell transplant (HCT) and are randomized to receive gilteritinib or placebo beginning after
the time of engraftment for a two year period.

This study will evaluate the efficacy, safety, tolerability, and pharmacodynamics of
entospletinib (GS-9973) when administered as monotherapy or in combination with chemotherapy
in adults with acute myeloid leukemia (AML).

Phase 1 will investigate maximum tolerated dose of OXi4503 as a single agent and in
combination with intermediate-dose cytarabine in subjects with relapsed/refractory AML or

Phase 2 will investigate overall response rate of OXi4503 in combination with
intermediate-dose cytarabine in 1) subjects with MDS after failure of 1 prior
hypomethylating agent (Arm A) and 2) subjects with relapsed and refractory AML after
treatment failure of up to 1 prior chemotherapy regimen (Arm B).